PDL BioPharma Inc

PDL BioPharma — Q1 2020 Earnings Presentation

15 slides from PDL BioPharma's earnings presentation, May 7, 2020

  1. Slide 1: First Quarter 2020 Financial Results Conference Call

    PDL First Quarter 2020 Financial Results Conference Call May 7, 2020 Nasdaq: PDLI

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: Additional Information and Where to Find It

    Additional Information and Where to Find It (On May 5, 2020, the Company filed a preliminary proxy statement and the Company plans to file a definitive proxy statement (the “2020 Proxy Statement’) with the USS. Securities and Exchange Commission (the “SEC? in connection with the solicitation of prox

  4. Slide 4: Progress Toward Asset Monetization

    Progress Toward Asset Monetization o Progressing with disciplined, cost-effective monetization strategy with focus on optimizing return of net proceeds to stockholders o Potential transactions include whole company sale, divestiture of assets, subsidiary or asset spin-off or combination of transacti

  5. Slide 5: Proposed Dissolution Plan

    Proposed Dissolution Plan o Virtual Annual Meeting of Stockholders is scheduled for July 16, 2020 with record date of May 29, 2020 o Our Board approved a plan of dissolution to be presented to stockholders o Approval of the Dissolution Plan requires approval by the holders of the majority our outsta

  6. Slide 6: Distribution of Evofem Common Stock

    Distribution of Evofem Common Stock o Board of Directors approved distribution of all 13.3 million shares of EVFM common stock held by PDL through special, one-time dividend o Decision made after careful consideration and consultation with advisors Torreya and SVB Leerink o EVFM shares to be distrib

  7. Slide 7: Strategy to Maximize Asset Value

    Strategy to Maximize Asset Value o Engaged leading investment banks as advisors; robust processes underway: = BofA Securities for sale of whole company or royalty portfolio = Torreya for sale of Noden = SVB Leerink to pursue pathway for LENSAR and advise on overall liquidation and distribution strat

  8. Slide 8: LENSAR: Innovation is Key Advantage

    LENSAR: Innovation is Key Advantage o COVID-19 has severely impacted elective cataract surgeries worldwide o Market assumed to progressively reopen in the latter part of Q2’20 starting in Asia and subsequently ramping in the rest of the world, with potential to exit 4Q’20 at pre-COVID-19 levels o At

  9. Slide 9: High-Quality Royalty Portfolio

    High-Quality Royalty Portfolio Tat mame samy tina men Glumetza | 3, Pevomea VALEANT| indefinite { ) FRB HK Depomed merce, 7018 Hentedieie2 He vevomes (Hien Ltt, 5/2026) ~ $260.6M — $463.4M vorcanes XR Depomed yanssen Jr 9/2023) gon 2G, Fk Devomea | DE Ya, 12120262 | J ToLusig =... ae Payoff $100.0M

  10. Slide 10: Noden: Focus on Profitability

    10 Noden: Focus on Profitability voven Pr riaraa o Focused on increasing the profitability of Tekturna® (aliskiren) and mitigating the impact of generic competition in the U.S. o Noden generated net operating income of $3.7 million in Q1’20 o Branded Tekturna® and our authorized generic together are

  11. Slide 11: $275 Million Share Repurchase Program

    $275 Million Share Repurchase Program o During the three months ended March 31, 2020, the Company repurchased $5.4 million in aggregate principal amount of 2021 Convertible Notes and $10.5 million in aggregate principal amount of 2024 Convertible Notes for cash payments totaling $18.0 million o Inth

  12. Slide 12: First Quarter 2020 Financials (unaudited)

    First Quarter 2020 Financials (unaudited) ‘Three Months Ended March 31, (lnthousands, except per share amourts) 2020 2019 Product revenue, net § 5985 § 6726 Royalties from Queen et al patents 3 License and other 40 33) Total revenues 5.005, 6.696 Cost of product revenue, (excluding intangible asset

  13. Slide 13: First Quarter 2020 Financials (unaudited)

    13 First Quarter 2020 Financials (unaudited) GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) GAAP net (loss) income attributed to PDL's shareholders, as reported Adjustments: Mark-to-market adjustmentto fair value - royalty assets Mark-to-market adjustments to equity affiliate - com

  14. Slide 14: First Quarter 2020 Financials (unaudited)

    First Quarter 2020 Financials (unaudited) Consolidated balance sheet data 5 March 31, December 31, (in thousands) 2020 2019 Cash and cash equivalents $ 125,512 $ 168,982 Notes receivable $ 53,299 $ 53,410 Assets held for sale $ 331,661 $ 350,366 Total assets $ 658,716 $ 716,119 Liabilities held for

  15. Slide 15: Questions & Answers

    PDL Questions & Answers

PDL BioPharma — Q1 2020 Earnings Presentation on 6ix